Japan’s Esai Tender Offer For MGI Pharma Of U.S. Passes 96 Percent
This article was originally published in PharmAsia News
Eisai says it has completed its tender offer for U.S. drug maker MGI Pharma after receiving an interest in selling from 96.1 percent of shareholders at the Eisai asking price. The Japanese firm said it extended its offer to the remaining shareholders through Jan. 25 in an attempt to own 100 percent. If the purchase is completed at a cost expected to reach $3.9 billion, Eisai plans to remove MGI Pharma from the U.S. stock market. (Click here for more - may be a subscription
You may also be interested in...
U.S. FDA has approved a new indication for Japan-based Eisai's Aloxi (palonosetron hydrochloride) for post-operative nausea and vomiting in the first 24 hours after surgery. The drug maker announced approval of the expanded indication March 3 for the drug it obtained through the acquisition of MGI Pharma earlier this year (PharmAsia News, Jan. 24, 2008).
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.